The California Institute for Regenerative Medicine (CIRM) presented key recommendations from its Strategic Allocation Framework (SAF), offering a structured, data‑driven approach to guide funding decisions and maximize impact. These recommendations, shared with the Independent Citizens’ Oversight Committee, move CIRM closer to its mission to accelerate the development and delivery of innovative regenerative medicine therapies. Evolving … Continue reading CIRM’s Key Recommendations from Strategic Allocation Framework
Month: September 2024
UC San Diego Gene Therapy Initiative Symposium fueling progress in the fieldÂ
Enthusiasm ran high at the inaugural UC San Diego Gene Therapy Initiative Symposium at the Roth Auditorium at the Sanford Consortium. Researchers, clinicians, and patient advocates gathered to share new discoveries in gene therapy—a rapidly evolving field that is reshaping modern medicine. CIRM served as a platinum sponsor of the event. Era of progress The … Continue reading UC San Diego Gene Therapy Initiative Symposium fueling progress in the fieldÂ
CIRM Supports Groundbreaking Gene Therapy for AML and MDS
Image source: Canva  The California Institute for Regenerative Medicine (CIRM) recently awarded $8 million to Rochelle Emery, MD, at Senti Bio to advance a clinical trial for a novel therapy targeting two forms of blood cancer, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). About AML and MDS Both cancers have a five-year survival rate … Continue reading CIRM Supports Groundbreaking Gene Therapy for AML and MDS
Strategic Framework Impacts the Future of CIRM’s Research FundingÂ
As the regenerative medicine field rapidly evolves, CIRM faces a key challenge: investing the remaining $3.86 billion in ways that deliver the greatest impact for Californians. To meet this challenge, CIRM launched the Strategic Allocation Framework (SAF) to prioritize resources and maximize the potential of regenerative medicine breakthroughs. What is the SAF? The SAF uses … Continue reading Strategic Framework Impacts the Future of CIRM’s Research FundingÂ
CIRM Supports Innovative Gene Therapy for Rare Heart Disorder
Image Source: American Heart Association Journals  The California Institute for Regenerative Medicine (CIRM) awarded $4 million to support a gene therapy for rare life-threatening genetic disorder. A rare heart disorder Known as desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM), the genetic disorder is a rare heart disorder.   This preclinical award went to Deborah D. Ascheim, … Continue reading CIRM Supports Innovative Gene Therapy for Rare Heart Disorder
CIRM awards boost clinical trials for cancer, heart, and rare diseases
The California Institute for Regenerative Medicine (CIRM) has allocated $26 million to support clinical research targeting cancers, heart conditions, and rare diseases. This investment reinforces CIRM’s commitment to advancing innovative stem cell and gene therapy treatments through all stages of clinical development. This round of awards funds five projects within CIRM’s Clinical Program, which provides … Continue reading CIRM awards boost clinical trials for cancer, heart, and rare diseases
Turning Hope into Reality: How a Genetic Therapy Helped Connor
Photo credit: n-Lorem Connor Dalby is a 15‑year‑old who loves music and the beach, but his journey has been anything but ordinary. He was diagnosed with a rare mutation in the SCN2A gene, bringing significant challenges into his life. A few weeks after birth, he struggled with sleep and persistent stomach issues. By eight months … Continue reading Turning Hope into Reality: How a Genetic Therapy Helped Connor